Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition
Pires da Silva, I.
Tondini, C. A.
Grimes, J. M.
Trager, M. H.
Vitale, M. G.
Rose, A. A. N.
Borgers, J. S. W.
Pimentel Muniz, T.
Saibil, S. D.
Butler, M. O.
Menzies, A. M.
Carlino, M. S.
Blank, C. U.
Sullivan, R. J.
Ascierto, P. A.
Miller, W. H., Jr.
Stephen Hodi, F.
Suijkerbuijk, K. P. M.
Reynolds, K. L.
Rahma, O. E.
Lorigan, Paul C
Carvajal, R. D.
Long, G. V.
AffiliationMelanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia.
MetadataShow full item record
AbstractBackground: Patients with cancer who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are more likely to develop severe illness and die compared with those without cancer. The impact of immune checkpoint inhibition (ICI) on the severity of COVID-19 illness is unknown. The aim of this study was to investigate whether ICI confers an additional risk for severe COVID-19 in patients with cancer. Methods: We analyzed data from 110 patients with laboratory-confirmed SARS-CoV-2 while on treatment with ICI without chemotherapy in 19 hospitals in North America, Europe and Australia. The primary objective was to decribe the clinical course and to identify factors associated with hospital and intensive care (ICU) admission and mortality. Findings: Thirty-five (32%) patients were admitted to hospital and 18 (16%) died. All patients who died had advanced cancer, and only four were admitted to ICU. COVID-19 was the primary cause of death in 8 (7%) patients. Factors independently associated with an increased risk for hospital admission were ECOG ≥2 (OR 39.25, 95% CI 4.17 to 369.2, p=0.0013), treatment with combination ICI (OR 5.68, 95% CI 1.58 to 20.36, p=0.0273) and presence of COVID-19 symptoms (OR 5.30, 95% CI 1.57 to 17.89, p=0.0073). Seventy-six (73%) patients interrupted ICI due to SARS-CoV-2 infection, 43 (57%) of whom had resumed at data cut-off. Interpretation: COVID-19-related mortality in the ICI-treated population does not appear to be higher than previously published mortality rates for patients with cancer. Inpatient mortality of patients with cancer treated with ICI was high in comparison with previously reported rates for hospitalized patients with cancer and was due to COVID-19 in almost half of the cases. We identified factors associated with adverse outcomes in ICI-treated patients with COVID-19.
CitationRogiers A, Pires da Silva I, Tentori C, Tondini CA, Grimes JM, Trager MH, et al. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. J Immunother Cancer. 2021;9(1).
JournalJournal for immunotherapy of cancer
- SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.
- Authors: Mandala M, Lorigan P, De Luca M, Bianchetti A, Merelli B, Bettini AC, Bonomi L, Nahm S, Vitale MG, Negrini G, Di Croce A, Ascierto PA, Rulli E, Tondini CA
- Issue date: 2021 Feb
- Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
- Authors: Luo B, Li J, Hou X, Yang Q, Zhou Y, Ye J, Wu X, Feng Y, Hu T, Xu Z, He Y, Sun J
- Issue date: 2021 Sep
- Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
- Authors: Yuen KCJ, Mortensen MJ, Azadi A, Fonkem E, Findling JW
- Issue date: 2021 Jul
- Does immune checkpoint inhibitor increase the risks of poor outcomes in COVID-19-infected cancer patients? A systematic review and meta-analysis.
- Authors: Lazarus G, Budiman RA, Rinaldi I
- Issue date: 2022 Feb
- Immune checkpoint inhibition in COVID-19: risks and benefits.
- Authors: Pezeshki PS, Rezaei N
- Issue date: 2021 Sep